Sanofi (SNY) Shares Sold by Boston Partners

Boston Partners reduced its stake in shares of Sanofi (NYSE:SNY) by 4.3% during the second quarter, Holdings Channel reports. The fund owned 8,161,184 shares of the company’s stock after selling 365,818 shares during the period. Boston Partners’ holdings in Sanofi were worth $391,002,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Fisher Asset Management LLC increased its position in shares of Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after buying an additional 1,022,953 shares during the last quarter. Bank of America Corp DE increased its position in shares of Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the last quarter. Brandes Investment Partners LP increased its position in shares of Sanofi by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock valued at $157,933,000 after buying an additional 102,511 shares during the last quarter. Finally, Hamlin Capital Management LLC increased its position in shares of Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock valued at $80,026,000 after buying an additional 186,280 shares during the last quarter. Hedge funds and other institutional investors own 9.96% of the company’s stock.

Shares of Sanofi (NYSE:SNY) opened at 47.75 on Thursday. The stock’s 50 day moving average price is $48.08 and its 200-day moving average price is $46.05. The company has a market cap of $119.92 billion, a P/E ratio of 11.28 and a beta of 0.88. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. The firm’s revenue was down 2.3% compared to the same quarter last year. Equities analysts expect that Sanofi will post $3.26 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/08/10/sanofi-sny-shares-sold-by-boston-partners.html.

SNY has been the subject of several research analyst reports. BidaskClub downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Friday, June 2nd. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Thursday, April 20th. Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research report on Monday, April 24th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $63.75.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply